Reiken et al from Columbia University extrapolate esoteric data from the neurochemistry of older patients with Alzheimer disease and finds similarities in this study neurocognitively impaired patients who died from COVID-19.
The main argument I find to dispel that this is simply a finding from 2 separate but very common comorbid conditions, is that the patients with COVID-19 had the pathological findings in the cerebellum which is not a location impacted by Alzheimer’s disease. They then promote their findings by stating IF this finding is true (increased activity on the ryanodine receptor) then MAYBE there is a POTENTIAL target for treatment.
Figure 4 might be of interest
JT
Joseph (Joe) E. Thornton, M.D., DFAPA
Reiken – Alzheimer s$B!>(Blike signaling in brains of COVID$B!>(B19 patients.pdf
Gator Psychiatry 